Sivik Global Healthcare’s Vertex Pharmaceuticals VRTX Stock Holding History

Sivik Global Healthcare’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.46M	Hold	10,000	–	–	3.39%	9
2026 Q1	$4.46M	Sell	10,000 -3,770	-27%	-$1.76M	3.39%	9
2025 Q4	$6.24M	Sell	13,770 -230	-2%	-$99.1K	1.81%	17
2025 Q3	$5.48M	Buy	+14,000	New	+$5.85M	1.6%	24
2025 Q1	–	Sell	-13,000	Closed	-$5.24M	–	44
2024 Q4	$5.24M	Buy	13,000 +3,000	+30%	+$1.39M	2.76%	16
2024 Q3	$4.65M	Sell	10,000 -5,000	-33%	-$2.4M	1.97%	25
2024 Q2	$7.03M	Buy	15,000 +4,000	+36%	+$1.74M	2.53%	14
2024 Q1	$4.6M	Sell	11,000 -1,500	-12%	-$634K	1.08%	32
2023 Q4	$5.09M	Buy	12,500 +40	+0.3%	+$14.8K	2.12%	29
2023 Q3	$4.33M	Sell	12,460 -1,540	-11%	-$539K	2.19%	27
2023 Q2	$4.93M	Sell	14,000 -1,000	-7%	-$337K	1.15%	29
2023 Q1	$4.73M	Hold	15,000	–	–	2.03%	27
2022 Q4	$4.33M	Buy	+15,000	New	+$4.57M	2.04%	26
2021 Q2	–	Sell	-15,000	Closed	-$3.22M	–	61
2021 Q1	$3.22M	Buy	+15,000	New	+$3.29M	1.18%	37
2020 Q3	–	Sell	-30,000	Closed	-$5.63M	–	59
2020 Q2	$5.63M	Buy	30,000 +5,000	+20%	+$1.36M	1.87%	23
2020 Q1	$4.43M	Sell	25,000 -7,500	-23%	-$1.72M	1.75%	26
2019 Q4	$7.12M	Sell	32,500 -7,500	-19%	-$1.52M	2.64%	15
2019 Q3	$6.78M	Buy	40,000 +10,000	+33%	+$1.77M	3.42%	6
2019 Q2	$5.5M	Hold	30,000	–	–	1.33%	19
2019 Q1	$5.52M	Sell	30,000 -5,000	-14%	-$924K	2.03%	22
2018 Q4	$5.8M	Hold	35,000	–	–	3.13%	11
2018 Q3	$6.75M	Sell	35,000 -8,600	-20%	-$1.53M	2.41%	15
2018 Q2	$7.41M	Buy	43,600 +8,600	+25%	+$1.33M	2.85%	6
2018 Q1	$5.7M	Sell	35,000 -10,000	-22%	-$1.63M	2.66%	11
2017 Q4	$6.74M	Sell	45,000 -5,000	-10%	-$740K	2.5%	8
2017 Q3	$7.6M	Sell	50,000 -5,000	-9%	-$753K	2.59%	10
2017 Q2	$7.09M	Buy	55,000 +5,000	+10%	+$602K	2.59%	9
2017 Q1	$5.47M	Buy	50,000 +10,000	+25%	+$880K	2.55%	12
2016 Q4	$2.95M	Sell	40,000 -10,000	-20%	-$814K	1.41%	29
2016 Q3	$4.36M	Sell	50,000 -15,000	-23%	-$1.42M	2.2%	24
2016 Q2	$5.59M	Buy	65,000 +45,000	+225%	+$3.89M	2.78%	6
2016 Q1	$1.59M	Sell	20,000 -10,000	-33%	-$905K	0.7%	52
2015 Q4	$3.77M	Sell	30,000 -10,000	-25%	-$1.21M	1.79%	23
2015 Q3	$4.17M	Buy	40,000 +23,000	+135%	+$2.95M	2.02%	21
2015 Q2	$2.1M	Buy	+17,000	New	+$2.14M	0.73%	53
2015 Q1	–	Sell	-14,900	Closed	-$1.77M	–	80
2014 Q4	$1.77M	Sell	14,900 -15,100	-50%	-$1.7M	0.72%	58
2014 Q3	$3.37M	Buy	30,000 +10,000	+50%	+$952K	1.53%	29
2014 Q2	$1.89M	Buy	+20,000	New	+$1.4M	0.96%	46

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Sivik Global Healthcare's VRTX Position: Q2 2026 in Review

Sivik Global Healthcare held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 10,000 shares worth $4.46M. The position accounts for 3.39% of the portfolio, ranked #9.

Sivik Global Healthcare first reported a position in VRTX in Q2 2014 and has held it in 38 quarters since. The position peaked at $7.6M in Q3 2017. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Sivik Global Healthcare held 10,000 shares of Vertex Pharmaceuticals worth $4.46M as of Q2 2026.
Sivik Global Healthcare left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 3.39% of Sivik Global Healthcare's portfolio in Q2 2026, its #9 holding.
Sivik Global Healthcare first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
Sivik Global Healthcare's Vertex Pharmaceuticals position peaked at $7.6M in Q3 2017.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sivik Global Healthcare's 13F filing for Q2 2026, filed 20 Jul 2026.